Citigroup Maintains Buy on Telix Pharmaceuticals, Lowers Price Target to $22

Benzinga · 07/07 18:25
Citigroup analyst Laura Sutcliffe maintains Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and lowers the price target from $22.5 to $22.